Frequency and diversity of human immunodeficiency virus type 1 mutations associated with antiretroviral resistance among patients from Southern Brazil failing highly active antiretroviral therapy (HAART)

International Journal of Molecular Medicine

Volumn 26, Issue 4, 2010, Pages 585-593

  Saad, Flavia Figueiredo ^a   Morimoto, Helena Kaminami ^a   Wiechmann, Susana Lilian ^a   Bonametti, Ana Maria ^a   Ueda, Luis Toshio ^b   Matsuo, Tiemi ^a   Reiche, Edna Maria Vissoci ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b Integrated Center of Infectious Diseases   (Brazil)

Author keywords

Antiretroviral resistance; Diversity; Human immunodeficiency; Virus evolution

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAZIL; CHILD; EPIDEMIC; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS MUTATION; VIRUS RESISTANCE;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CHILD; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; YOUNG ADULT;

EID: 77957876979     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm-00000503     Document Type: Article

References (53)

1. Thomson MM, Pérez-Álvarez L and Nájera R: Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2: 461-471, 2002.
2. Perrin L, Kaiser L and Yerly S: Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 3: 22-27, 2001.
3. Dumans AT, Soares MA, Pieniazek D, et al: Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrob Agents Chemother 46: 3075-3079, 2002.
4. Tanuri A, Caride E, Dantas MC, et al: Prevalence of mutations related to HIV-1 anti-retroviral resistance in Brazilian patients failing HAART. J Clin Virol 25: 39-46, 2002.
5. Shafer RW and Schapiro JM: HIV-1 drug resistance mutations: an update framework for the second decade of HAART. AIDS Rev 10: 67-84, 2008.
6. Brindeiro R, Vanderborght B, Caride E, et al: Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals. Antimicrob Agents Chemother 43: 1674-1680, 1999. (Pubitemid 29331246)
7. Pires IL, Soares MA, Speranza FAB, et al: Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naïve, infected individuals in the Army Health Service of Rio de Janeiro, Brazil. J Clin Microbiol 42: 426-430, 2004.
8. Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, et al: Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 individuals failing highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 100: 73-78, 2005.
9. Machado DM, Fernandes SC, Succi RCM, et al: Analysis of HIV-1 protease and reverse transcriptase in Brazilian children failing highly active anti-retroviral therapy (HAART). Rev Inst Med Trop São Paulo 46: 1-5, 2005.
10. Rodrigues R, Vazquez CM, Colares JK, et al: Anti-retroviral resistance mutations in human immunodeficiency virus type 1 infected patients enrolled in genotyping testing at the Central Public Health Laboratory, São Paulo, Brazil: preliminary results. Mem Inst Oswaldo Cruz 100: 97-102, 2005.
11. Eyer-Silva WA and Morgado MG: A genotyping study of human immunodeficiency virus type-1 drug resistance in a small Brazilian municipality. Mem Inst Oswaldo Cruz 100: 869-873, 2005.
12. Szwarcwald CL, Bastos FI, Esteves MA and de Andrade CI: A disseminação da epidemia da AIDS no Brasil, no período de 1987-1996: uma análise espacial. Cad Saúde Pública 16: 7-19, 2000.
13. Reiche EVM, Bonametti AM, Watanabe MAE, et al: Sociodemographic and epidemiological characteristics associated with human immunodeficiency virus type 1 (HIV-1) infection in HIV-1-exposed but uninfected individuals, and in HIV-1-infected patients from a southern Brazilian population. Rev Inst Med Trop S Paulo 47: 239-246, 2005.
14. Brazil. Ministry of Health. Epidemiologic Buletin Aids. STD and AIDS Coordination. Brasília: Ministry of Health. Year XVII, n. 1, 01 to 52 epidemiologic weeks January to December 2003.
15. Brazil. Ministry of Health. Recommendations for the antiretroviral therapy in adults and adolescents HIV-infected, 2008.
16. Brazil. Ministry of Health. Manual of adherence in the treatment for persons living with HIV and AIDS. Serie A. Norms and Technical Manual. Manual Series. n.84. Brasília: Ministry of Health, 130p. 2008.
17. Brazil. Ministry of Health. Secretariat of Health Politics. STD and AIDS National Coordination. Review of the Definition of AIDS case in individual with 13 years old or more, to the epidemiologic surveillance. Brasília, Ministry of Health, 1998.
18. Taylor-Castillo L, Herrera-Martínez G, León-Bratti MP, et al: Study of antiretroviral mutants in HIV patients with treatment failures and the effect of risk factors in the virological failures. Rev Inst Med Trop S. Paulo 47: 327-331, 2005.
19. Cerqueira DM, Amorim RMS, Silva RR, Camara GNL, Brigido MM and Martins CRF: Anti-retroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil. Mem Inst Oswaldo Cruz 99: 877-882, 2004.
20. Soares MA, Brindeiro RM and Tanuri A: Primary HIV-1 drug resistance in Brazil. AIDS 18 (Suppl 3): 9-13, 2004.
21. Gonsalez CR, Alcalde R, Nishiya A, et al: Drug resistance among chronic HIV-1-infected patients naïve for use of antiretroviral therapy in São Paulo city. Virus Res 129: 87-90, 2007.
22. Rhee S, Liu T, Ravela J, Gonzales M and Shafer R: Distribution of HIV-1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotyping resistance testing. Antimicrob Agents Chemother 48: 3122-3126, 2004. (Pubitemid 38989184)
23. Machado ES, Lambert JS, Watson DC, et al: Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy. J Clin Virol 30: 24-31, 2004.
24. Iafrate AJ: Clinical testing for HIV-1 drug resistance. Clin Microbiol Newsletter 26: 33-37, 2004.
25. Nijhius M, Schuurman R, De Jong D, et al: Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis 176: 398-405, 2007.
26. Gallego O, Briones C, Corral A, et al: Prevalence of novel lamivudine-resistant genotypes (E44D/A, V118I) in naive and pretreated HIV-infected individual. J Acquir Immune Defic Syndr 25: 95-96, 2000.
27. Stürmer M, Staszewski S, Doerr HW, Larder B, Bloor S and Hertogs K: Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: Interpretation of established mutations and characterization of new polymorphisms at codons 208, 211 and 214. Antimicrob Agents Chemother 47: 54-61, 2003.
28. Torti C, Gilleece I, Hertogs K, Gazzard BG and Pozniak AL: R211K and L214F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naïve patients with M184V. J Acquir Immune Defic Syndr 26: 514-515, 2001. (Pubitemid 32489036)
29. Rhee S, Taylor J, Wadhera G, Bem-Hur A, Bruttag D and Shafer R: Genotypic predictors of HIV-1 drug resistance. Proc Natl Acad Sci USA 103: 17355-17360, 2006.
30. Bacheler L, Jeffrey S, Hanna G, et al: Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing NNRTI therapy. J Virol 75: 4999-5008, 2001.
31. Vingerhoets J, Azjn H, Fransen E, et al: TMC 125 displays a high genetic barrier to the development of resistance from in vitro selection experiments. J Virol 79: 12773-12782, 2005.
32. Zolopa A, Shafer R, Warford A, et al: HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous PI therapy had failure. Ann Intern Med 131: 813-821, 1999.
33. Marcelin A, Dalban C, Peylavin G, et al: Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in HIV-1 PI-experienced patients. Antimicrob Agents Chemother 48: 4687-4692, 2004.
34. Marcelin A, Flandre P, de Mendoza C, et al: Clinical validation of saquinavir/ritonavir genotypic resistance score in PI-experimented patients. Antivir Ther 12: 247-252, 2007.
35. Dandache S, Sevigny G, Yelle J, et al: In vitro antiviral activity and cross-resistance profile of PL-100, a novel PI of HIV-1. Antimicrob Agents Chemother 51: 4036-4043, 2007.
36. Pellegrin I, Breih D, Coureau G, et al: Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. Antimicrob Agents Chemother 51: 1473-1480, 2007.
37. Masquelier B, Assoumou K, Descamps D, et al: Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. J Antimicrob Chemother 61: 1362-1368, 2008. (Pubitemid 351760775)
38. Mammano F, Petit C and Clavel F: Resistance-associated loss of viral fitness in HIV-1 phenotypic analysis of protease and gag co-evolution in PI-treated patients. J Virol 72: 7632-7637, 1998.
39. Nijhuis M, Schuman R, de Jong D, et al: Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13: 2349-2359, 1999.
40. Martinez-Picado J, Savara A, Sutton L and D'Aquila R: Replicative fitness of PI-resistant mutants of HIV-1. J Virol 73: 3744-3752, 1999.
41. Van Maarseveen N, de Jong D, Boucher C and Nijhuis M: An increase in viral replicative capacity drivers the evolution of PI-resistant HIV-1 in the absence of drugs. J Acquir Immune Defic Syndr 42: 162-168, 2006.
42. Hoffman N, Schiffer C and Swanstrom R: Covalidation of amino acid positions in HIV-1 protease. Virology 314: 536-548, 2003.
43. Barreto CC, Nishyia A, Araújo LV, Ferreira JE, Busch MP and Sabino EC: Trends in antiretroviral drug resistance and clade distributions among HIV-1-infected blood donors in São Paulo, Brazil. J Acquir Immune Defic Syndr 41: 338-341, 2006.
44. Sá-Ferreira JA, Brindeiro PA, Chequer-Fernandez S, Tanuri A and Morgado MG: Human immunodeficiency virus-1 and antiretroviral drug resistance profiles among drug-naïve Brazilian blood donors. Transfusion 47: 97-102, 2007.
45. Dumans AT, Barreto CC, Santos AF, et al: Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure. Infect Genet Evol 9: 62-70, 2009.
46. Gross KL, Porco TC and Grant RM: HIV-1 superinfection and viral diversity. AIDS 18: 1513-1520, 2004.
47. Fultz PN: HIV-1 superinfections: omens for vaccine efficacy? AIDS 18: 115-119, 2004.
48. Grossman Z, Istomin V, Averbuch D, et al: AIDS Multi-Center Study Group: genetic variations at ITRNN resistance-associated positions in patients infected with HIV-1-subtype C. AIDS 18: 900-915, 2004.
49. Brenner B, Turner D, Oliveira M, et al: A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17: 1-5, 2003.
50. Bartlett JG and Gallant JE: Medical Management of HIV Infection. Johns Hopkins University, Baltimore, pp22-26, 2003.
51. Simon V, Vanderhoeven J, Hurley A, et al: Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 16: 1511-1519, 2002. (Pubitemid 34804216)
52. Boden D, Hurley A, Zhang L, et al: HIV-1 drug resistance in newly infected individuals. JAMA 282: 1135-1141, 1999.
53. Ferreira FGF, Pinto JÁ, Kakehasi FM, et al: Prevalence of primary drug resistance-associated mutations among HIV type 1 vertically infected children in Belo Horizonte, Brazil. AIDS Res Human Retroviruses 26: 229-232, 2010.